Literature DB >> 29898972

Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease.

Koji Kasanuki1, Keith A Josephs1, Tanis J Ferman1, Melissa E Murray1, Shunsuke Koga1, Takuya Konno1, Nobutaka Sakae1, Adam Parks1, Ryan J Uitti1, Jay A Van Gerpen1, Neill R Graff-Radford1, Zbigniew K Wszolek1, Dennis W Dickson2.   

Abstract

OBJECTIVE: To describe clinical and pathologic characteristics of diffuse Lewy body disease (DLBD) manifesting as corticobasal syndrome (CBS).
METHODS: In 523 autopsy-confirmed cases of DLBD, we identified 11 patients diagnosed with CBS. For comparison, we studied 22 DLBD brains with antemortem presentation of dementia with Lewy bodies (DLB). Given previous studies suggesting the importance of pathology in peri-Rolandic cortices in CBS, we used digital pathology to count Lewy bodies and to quantify intracytoplasmic and neuritic α-synuclein and phospho-tau burden in the motor cortex.
RESULTS: DLBD patients with antemortem features of CBS were significantly younger at disease onset and less likely to have REM sleep behavior disorder than DLBD cases who met clinical criteria for DLB during life. Patients with DLBD manifesting as CBS had more Lewy bodies in the motor cortex than DLBD manifesting as clinically probable DLB. Three cases had concomitant progressive supranuclear palsy and 4 cases had concomitant Alzheimer disease as probable correlates of CBS.
CONCLUSION: The neuropathology underlying CBS is heterogeneous, including corticobasal degeneration, Alzheimer disease, and progressive supranuclear palsy. This study suggests that atypical variants of Lewy body disease with severe peri-Rolandic Lewy-related pathology can present clinically as CBS. Patients with DLBD who present as CBS tend to have an earlier age at onset and are less likely to have clinical features of DLB, such as dream enactment behavior during sleep, visual hallucinations, and levodopa-responsive parkinsonism. Future studies with biofluid or molecular imaging biomarkers for α-synuclein will permit better recognition of this uncommon pathologic substrate of CBS.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29898972      PMCID: PMC6059030          DOI: 10.1212/WNL.0000000000005828

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome.

Authors:  Naomi Kouri; Melissa E Murray; Anhar Hassan; Rosa Rademakers; Ryan J Uitti; Bradley F Boeve; Neill R Graff-Radford; Zbigniew K Wszolek; Irene Litvan; Keith A Josephs; Dennis W Dickson
Journal:  Brain       Date:  2011-09-20       Impact factor: 13.501

2.  Imaging amyloid deposition in Lewy body diseases.

Authors:  S N Gomperts; D M Rentz; E Moran; J A Becker; J J Locascio; W E Klunk; C A Mathis; D R Elmaleh; T Shoup; A J Fischman; B T Hyman; J H Growdon; K A Johnson
Journal:  Neurology       Date:  2008-09-16       Impact factor: 9.910

3.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

4.  Diffuse lewy body disease presenting as corticobasal syndrome and progressive supranuclear palsy syndrome.

Authors:  Aaron Haug; Philip Boyer; Benzi Kluger
Journal:  Mov Disord       Date:  2013-02-07       Impact factor: 10.338

5.  Pathology and sensitivity of current clinical criteria in corticobasal syndrome.

Authors:  Haruka Ouchi; Yasuko Toyoshima; Mari Tada; Mutsuo Oyake; Izumi Aida; Itsuro Tomita; Akira Satoh; Mitsuhiro Tsujihata; Hitoshi Takahashi; Masatoyo Nishizawa; Takayoshi Shimohata
Journal:  Mov Disord       Date:  2013-11-20       Impact factor: 10.338

Review 6.  Alzheimer's disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration.

Authors:  D S Horoupian; P H Wasserstein
Journal:  Acta Neuropathol       Date:  1999-09       Impact factor: 17.088

7.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy brain bank.

Authors:  Keith A Josephs; Dennis W Dickson
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

Review 8.  Levodopa responsiveness in disorders with parkinsonism: a review of the literature.

Authors:  Radu Constantinescu; Irene Richard; Roger Kurlan
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

Review 9.  Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium.

Authors:  Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka
Journal:  Neurology       Date:  2017-06-07       Impact factor: 9.910

10.  In vivo retention of 18F-AV-1451 in corticobasal syndrome.

Authors:  Ruben Smith; Michael Schöll; Håkan Widner; Danielle van Westen; Per Svenningsson; Douglas Hägerström; Tomas Ohlsson; Jonas Jögi; Christer Nilsson; Oskar Hansson
Journal:  Neurology       Date:  2017-07-28       Impact factor: 9.910

View more
  14 in total

1.  Cerebrovascular pathology presenting as corticobasal syndrome: An autopsy case series of "vascular CBS".

Authors:  Shunsuke Koga; Shanu F Roemer; Koji Kasanuki; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2019-09-02       Impact factor: 4.891

2.  Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype.

Authors:  Marina Buciuc; Jennifer L Whitwell; Koji Kasanuki; Jonathan Graff-Radford; Mary M Machulda; Joseph R Duffy; Edythe A Strand; Val J Lowe; Neill R Graff-Radford; Beth K Rush; Malgorzata B Franczak; Margaret E Flanagan; Matthew C Baker; Rosa Rademakers; Owen A Ross; Bernardino F Ghetti; Joseph E Parisi; Aditya Raghunathan; R Ross Reichard; Eileen H Bigio; Dennis W Dickson; Keith A Josephs
Journal:  Ann Neurol       Date:  2020-12-17       Impact factor: 10.422

3.  Corticobasal syndrome with visual hallucinations and probable REM-sleep behavior disorder: an autopsied case report of a patient with CBD and LBD pathology.

Authors:  George Naasan; Tal Shany-Ur; Manu Sidhu; Cynthia Barton; Robin Ketelle; Suzanne M Shdo; Joel H Kramer; Bruce L Miller; William W Seeley
Journal:  Neurocase       Date:  2019-04-22       Impact factor: 0.881

4.  Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome.

Authors:  Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Jay van Gerpen; Neil R Graff-Radford; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-08-06       Impact factor: 16.655

5.  Diffuse Lewy body disease manifesting as corticobasal syndrome: A rare form of Lewy body disease.

Authors: 
Journal:  Neurology       Date:  2018-11-20       Impact factor: 11.800

6.  Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy.

Authors:  Chiara Maria Giulia De Luca; Antonio Emanuele Elia; Sara Maria Portaleone; Federico Angelo Cazzaniga; Martina Rossi; Edoardo Bistaffa; Elena De Cecco; Joanna Narkiewicz; Giulia Salzano; Olga Carletta; Luigi Romito; Grazia Devigili; Paola Soliveri; Pietro Tiraboschi; Giuseppe Legname; Fabrizio Tagliavini; Roberto Eleopra; Giorgio Giaccone; Fabio Moda
Journal:  Transl Neurodegener       Date:  2019-08-08       Impact factor: 8.014

Review 7.  Neuropathology and molecular diagnosis of Synucleinopathies.

Authors:  Shunsuke Koga; Hiroaki Sekiya; Naveen Kondru; Owen A Ross; Dennis W Dickson
Journal:  Mol Neurodegener       Date:  2021-12-18       Impact factor: 14.195

8.  Presence of Skin α-Synuclein Deposits Discriminates Parkinson's Disease from Progressive Supranuclear Palsy and Corticobasal Syndrome.

Authors:  Maria Pia Giannoccaro; Patrizia Avoni; Giovanni Rizzo; Alex Incensi; Rossella Infante; Vincenzo Donadio; Rocco Liguori
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.568

9.  Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum.

Authors:  Kunal C Potnis; Lauren B Flueckinger; Stephanie M DeArmey; Roy N Alcalay; Jeffrey W Cooney; Priya S Kishnani
Journal:  Mol Genet Metab Rep       Date:  2018-10-18

10.  Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease.

Authors:  Zerui Wang; Katelyn Becker; Vincenzo Donadio; Sandra Siedlak; Jue Yuan; Masih Rezaee; Alex Incensi; Anastasia Kuzkina; Christina D Orrú; Curtis Tatsuoka; Rocco Liguori; Steven A Gunzler; Byron Caughey; Maria E Jimenez-Capdeville; Xiongwei Zhu; Kathrin Doppler; Li Cui; Shu G Chen; Jiyan Ma; Wen-Quan Zou
Journal:  JAMA Neurol       Date:  2020-09-28       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.